Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...
According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...
ZME Science on MSN
Inside the Human Gene Editing Boom Driven by CRISPR Reshaping Everything From Medicine to Food
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...
CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
A single infusion of CRISPR Therapeutics' experimental gene therapy was safe and reduced levels of harmful LDL cholesterol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback